- Home
- PMM vs ANNX Comparison
PMM vs ANNX Comparison
Compare PMM & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMM
- ANNX
- Stock Information
- Founded
- PMM 1989
- ANNX 2011
- Country
- PMM United States
- ANNX United States
- Employees
- PMM N/A
- ANNX N/A
- Industry
- PMM Investment Managers
- ANNX Biotechnology: Pharmaceutical Preparations
- Sector
- PMM Finance
- ANNX Health Care
- Exchange
- PMM Nasdaq
- ANNX Nasdaq
- Market Cap
- PMM 265.3M
- ANNX 252.3M
- IPO Year
- PMM N/A
- ANNX 2020
- Fundamental
- Price
- PMM $5.89
- ANNX $2.39
- Analyst Decision
- PMM
- ANNX Strong Buy
- Analyst Count
- PMM 0
- ANNX 4
- Target Price
- PMM N/A
- ANNX $12.50
- AVG Volume (30 Days)
- PMM 118.3K
- ANNX 1.4M
- Earning Date
- PMM 01-01-0001
- ANNX 08-11-2025
- Dividend Yield
- PMM 4.68%
- ANNX N/A
- EPS Growth
- PMM N/A
- ANNX N/A
- EPS
- PMM 0.23
- ANNX N/A
- Revenue
- PMM N/A
- ANNX N/A
- Revenue This Year
- PMM N/A
- ANNX N/A
- Revenue Next Year
- PMM N/A
- ANNX N/A
- P/E Ratio
- PMM $26.52
- ANNX N/A
- Revenue Growth
- PMM N/A
- ANNX N/A
- 52 Week Low
- PMM $5.00
- ANNX $1.29
- 52 Week High
- PMM $6.42
- ANNX $7.85
- Technical
- Relative Strength Index (RSI)
- PMM 48.88
- ANNX 54.03
- Support Level
- PMM $5.86
- ANNX $2.25
- Resistance Level
- PMM $5.93
- ANNX $2.49
- Average True Range (ATR)
- PMM 0.04
- ANNX 0.19
- MACD
- PMM 0.01
- ANNX -0.03
- Stochastic Oscillator
- PMM 63.64
- ANNX 24.56
About PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
About ANNX Annexon Inc.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.